Updated 2023 GOLD Report Revises COPD Definitions and …
The 2023 report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) — “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease” (COPD) 1 — details “an expanded range of therapies for COPD that now can be considered to improve mortality,” according to Gerard J. Criner, MD, FACP, FACCP, an author of the 2023 GOLD ...
GOLD COPD Report 2025: Key Spirometry and Drug Updates
Nov 22, 2024 · The COPD report chapter on “Non-pharmacological treatment of stable COPD” includes information about in-person and virtual delivery of pulmonary rehabilitation, education, and self-management. At the recent GOLD COPD conference, Vogelmeier told attendees that this section would undergo major revision in 2026.
2024 GOLD Report Reflects New Research on COPD Management
Dec 8, 2023 · The 2024 GOLD Report, “Global Strategy for Prevention Diagnosis and Management of COPD,” not only includes guideline updates that reflect the latest research on chronic obstructive pulmonary disease (COPD); it also reflects some shifts in thinking about what’s important in COPD treatment, according to Claus Vogelmeier, MD, a lead report author and science committee chair for the Global ...
GINA 2024 Asthma Update: Revised Recommendations on …
Jun 28, 2024 · Children: Initial Treatment Recommendations. Initial asthma treatment recommendations in children aged 6 to 11 years also have been updated. Symptom levels and lung function for initial treatment steps are similar to those for adults and adolescents. Additional details have been provided about studies, populations, and outcomes in this age group.
Dupixent Approved as Add-On Maintenance Therapy in COPD
Oct 1, 2024 · Treatment with dupilumab reduced the annualized rate of moderate or severe COPD exacerbations by 30% in the BOREAS trial and 34% in the NOTUS trial compared with placebo. The Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary ...
COPD Exacerbations and NAC - Pulmonology Advisor
Apr 17, 2023 · Review and meta-analysis limitations included the use of 4 studies with high risk of bias; heterogeneity in the 9 included studies for NAC treatment dose; concomitant COPD treatment; differences in therapy duration; and unknown synergistic effects in patients using oral high-dose NAC (more than 1200mg/day) and inhaled therapy with long-acting ...
Insomnia Treatment in COPD: Zolpidem No Less Safe Than Other …
Dec 1, 2023 · Participants were assigned a VA primary care provider, had at least 2 clinical encounters with COPD within a rolling 12-month period, and had a history of long-term use of inhaled treatment for COPD. Participants had index dates from January 1, 2010, to March 30, 2018, and were followed for a 3-month exposure assessment period and then a 1-year ...
Holistic Approach to COPD Needed to Address Unmet Patient …
Jan 22, 2024 · All had been diagnosed with COPD for at least 6 months and had stable symptoms of varying severity (56% had severe COPD). The current findings show that an apparent discrepancy exists between the traditional lung functional and pharmacological approaches in diagnosing and managing COPD and patient’s needs and challenges in daily activities.
Tezepelumab Gets Breakthrough Therapy Status for COPD Tx
Aug 12, 2024 · The primary endpoint was COPD exacerbation rate. Findings showed in the overall population, treatment with tezepelumab led to a 17% reduction (90% CI, -6, 36; P =.1042) in the annual rate of moderate to severe COPD exacerbations compared with placebo (annualized rate of exacerbations: 1.75 with tezepelumab vs 2.11 with placebo).
Trends That Will Transform Asthma Care in 2022
Jan 7, 2022 · Tezspire, a monoclonal antibody used as an add-on maintenance treatment for patients 12 years of age and older with severe asthma, is administered subcutaneously to patients by a health care provider once every 4 weeks. 3-5 “I think it’s going to be a real game-changer for those people who have not responded to the agents that we’ve had ...